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BACKGROUND
The management of complex orthopedic infections usually includes a prolonged 
course of intravenous antibiotic agents. We investigated whether oral antibiotic ther-
apy is noninferior to intravenous antibiotic therapy for this indication.
METHODS
We enrolled adults who were being treated for bone or joint infection at 26 U.K. centers. 
Within 7 days after surgery (or, if the infection was being managed without surgery, 
within 7 days after the start of antibiotic treatment), participants were randomly as-
signed to receive either intravenous or oral antibiotics to complete the first 6 weeks 
of therapy. Follow-on oral antibiotics were permitted in both groups. The primary end 
point was definitive treatment failure within 1 year after randomization. In the analysis 
of the risk of the primary end point, the noninferiority margin was 7.5 percentage points.
RESULTS
Among the 1054 participants (527 in each group), end-point data were available for 
1015 (96.3%). Treatment failure occurred in 74 of 506 participants (14.6%) in the intra-
venous group and 67 of 509 participants (13.2%) in the oral group. Missing end-point 
data (39 participants, 3.7%) were imputed. The intention-to-treat analysis showed a 
difference in the risk of definitive treatment failure (oral group vs. intravenous group) 
of −1.4 percentage points (90% confidence interval [CI], −4.9 to 2.2; 95% CI, −5.6 to 
2.9), indicating noninferiority. Complete-case, per-protocol, and sensitivity analyses 
supported this result. The between-group difference in the incidence of serious adverse 
events was not significant (146 of 527 participants [27.7%] in the intravenous group 
and 138 of 527 [26.2%] in the oral group; P = 0.58). Catheter complications, analyzed as 
a secondary end point, were more common in the intravenous group (9.4% vs. 1.0%).
CONCLUSIONS
Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used 
during the first 6 weeks for complex orthopedic infection, as assessed by treatment 
failure at 1 year. (Funded by the National Institute for Health Research; OVIVA Current 
Controlled Trials number, ISRCTN91566927.)
A BS TR AC T
Oral versus Intravenous Antibiotics for Bone 
and Joint Infection
H.-K. Li, I. Rombach, R. Zambellas, A.S. Walker, M.A. McNally, B.L. Atkins, 
B.A. Lipsky, H.C. Hughes, D. Bose, M. Kümin, C. Scarborough, P.C. Matthews, 
A.J. Brent, J. Lomas, R. Gundle, M. Rogers, A. Taylor, B. Angus, I. Byren, 
A.R. Berendt, S. Warren, F.E. Fitzgerald, D.J.F. Mack, S. Hopkins, J. Folb, 
H.E. Reynolds, E. Moore, J. Marshall, N. Jenkins, C.E. Moran, A.F. Woodhouse, 
S. Stafford, R.A. Seaton, C. Vallance, C.J. Hemsley, K. Bisnauthsing, J.A.T. Sandoe, 
I. Aggarwal, S.C. Ellis, D.J. Bunn, R.K. Sutherland, G. Barlow, C. Cooper, C. Geue, 
N. McMeekin, A.H. Briggs, P. Sendi, E. Khatamzas, T. Wangrangsimakul, 
T.H.N. Wong, L.K. Barrett, A. Alvand, C.F. Old, J. Bostock, J. Paul, G. Cooke, 
G.E. Thwaites, P. Bejon, and M. Scarborough, for the OVIVA Trial Collaborators* 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on November 14, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;5 nejm.org January 31, 2019426
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Complex bone and joint infections are typically managed with surgery and a prolonged course of treatment with intra-
venous antibiotic agents.1,2 The preference for 
intravenous antibiotics reflects a broadly held 
belief that parenteral therapy is inherently su-
perior to oral therapy,3 a view supported by an 
influential 1970 article that suggested that 
“. . . osteomyelitis is rarely controlled without 
the combination of careful, complete surgical 
debridement and prolonged (four to six weeks) 
parenteral antibiotic therapy . . . .” 4 However, 
intravenous therapy is associated with substan-
tial risks, inconvenience, and higher costs than 
oral therapy.5,6 A meta-analysis involving 180 pa-
tients with chronic osteomyelitis, 118 of whom 
were followed for more than 1 year, showed no 
advantage of intravenous therapy over oral ther-
apy, but there was insufficient evidence to draw 
conclusions with potential clinical utility.7 We 
therefore conducted a pragmatic noninferiority 
trial to evaluate outcomes at 1 year after intrave-
nous therapy as compared with oral therapy ad-
ministered during the initial 6 weeks of treat-
ment for orthopedic infection.
Me thods
Trial Design and Participants
Oral versus Intravenous Antibiotics for Bone and 
Joint Infection (OVIVA) was a multicenter, open-
label, parallel-group, randomized, controlled non-
inferiority trial. Blinding was not used, because 
we considered it unethical to expose participants 
in the oral group to the risks associated with 
prolonged courses of intravenously administered 
placebo. The methodologic details of the trial, 
summarized below, are presented in detail in 
the published protocol,8 which is also available 
with the full text of this article at NEJM.org. The 
trial was approved by the U.K. National Research 
Ethics Committee South Central. The first, sec-
ond, and last authors wrote the first draft of the 
manuscript. The authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol.
Eligible participants were older than 18 years 
of age, provided written informed consent, and, 
in the attending physician’s opinion, would ordi-
narily have been treated with 6 weeks of intrave-
nous antibiotic therapy for one of the following 
acute or chronic bone or joint infections: native 
osteomyelitis of the extraaxial skeleton, native 
joint infection requiring excision arthroplasty, 
prosthetic joint infection, orthopedic fixation-
device infection, or vertebral osteomyelitis with 
or without associated diskitis or soft-tissue in-
fection.
Randomization and Interventions
The statistician prepared a concealed, computer-
generated, 1:1 randomization list, using variably 
sized permuted blocks, with participants strati-
fied according to center. Randomization was 
performed by trained staff members using a 
centralized assignment system.
Participants began their randomly assigned 
treatment strategy as soon as possible (but no 
more than 7 days) after definitive surgical inter-
vention or, if the infection was being managed 
conservatively, the start of antibiotic therapy. 
Antibiotics were selected by accredited infection 
specialists with such factors as local epidemiol-
ogy, antimicrobial susceptibility, bioavailability, 
previous infections, contraindications, allergies, 
and drug interactions taken into account; the 
choice of antibiotic was therefore assumed to be 
the most appropriate therapy for each participant.
In the intravenous group, adjunctive oral 
agents such as rifampin were permitted at the 
infection specialist’s discretion, reflecting usual 
practice.9 In the oral group, up to 5 consecutive 
days of intravenous antibiotics were allowed for 
unrelated intercurrent infections. Antibiotics ad-
ministered before definitive treatment, as well 
as follow-on therapy beyond 6 weeks, were per-
mitted in both groups but were not governed by 
the trial protocol.
Assessments, Objectives, and End Points
Clinical assessments and patient-reported out-
come measures were recorded at enrollment and 
at days 42, 120, and 365. Adherence to treatment 
was assessed at days 14 and 42.
The primary end point was definite treatment 
failure within 1 year after randomization, defined 
as the presence of at least one clinical criterion 
(draining sinus tract arising from bone or pros-
thesis or the presence of frank pus adjacent to 
bone or prosthesis), microbiologic criterion 
(phenotypically indistinguishable bacteria isolat-
ed from two or more deep-tissue samples or a 
pathogenic organism from a single closed aspi-
rate or biopsy), or histologic criterion (presence 
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of characteristic inflammatory infiltrate or micro-
organisms). All potential primary end-point events, 
which were identified by local active surveillance 
during follow-up, were subsequently categorized 
by an end-point committee of three independent 
specialists who were unaware of the trial-group 
assignments. The members of the committee 
determined the category of each event by con-
sensus. There were four categories, which were 
based on predefined criteria: uninfected, possi-
ble treatment failure, probable treatment failure, 
or definite treatment failure (see the Supplemen-
tary Appendix, available at NEJM.org).
Secondary end points were probable or pos-
sible treatment failure, early discontinuation of 
the randomly assigned treatment strategy, intra-
venous catheter complications, Clostridium difficile–
associated diarrhea, serious adverse events, re-
source use, health status (measured with the 
three-level version of the European Quality of 
Life–5 Dimensions [EQ-5D-3L]),10 the Oxford 
Hip and Knee Scores,11 and adherence to treat-
ment (based on the Morisky Medication Adher-
ence Scale [scores range from 0 to 8, with higher 
scores indicating better adherence] or the Medi-
cation Event Monitoring System12,13).
Statistical Analysis
The sample size of 1050 participants was based 
on a 5% anticipated rate of treatment failure (the 
rate that was observed during a single-center 
pilot study), a 5-percentage-point noninferiority 
margin on the absolute risk difference scale 
(corresponding to a relative difference of 100%), 
with a one-sided alpha level of 0.05, 90% power, 
and 10% loss to follow-up. The 5-percentage-
point noninferiority margin was based on a 
consensus among a wide range of researchers, 
infectious-disease specialists, and orthopedic sur-
geons and balanced the potential risks and bene-
fits of oral therapy. In February 2015, after 601 
participants had undergone randomization in 
the multicenter trial, a planned interim analysis 
showed an overall failure rate of approximately 
12.5%. The original 5-percentage-point margin 
was consequently considered too restrictive and 
therefore, by consensus, the investigators adjust-
ed the noninferiority margin to 7.5 percentage 
points on the absolute risk difference scale (corre-
sponding to a 60% relative difference) with ap-
proval from the trial steering committee, data and 
safety monitoring committee, and ethics com-
mittee. Further information is provided in the 
Supplementary Appendix.
In the primary intention-to-treat analysis, pro-
portions of participants with definite treatment 
failure at 1 year were compared with the use of 
multiple imputation by chained equations for 
missing end-point data.14 Noninferiority was met 
if the upper limit of two-sided 90% confidence 
interval around the unadjusted absolute differ-
ence in risk (i.e., the risk in the oral group minus 
the risk in the intravenous group) was less than 
7.5 percentage points (in accordance with the 
sample-size calculation). Two-sided 95% confi-
dence intervals were also estimated. The modi-
fied intention-to-treat analysis included only the 
participants with complete end-point data. The 
per-protocol analysis included only participants 
who received at least 4 weeks of their randomly 
assigned treatment. For sensitivity analyses, miss-
ing end-point data were replaced by treatment 
failure in the oral group and success in the intra-
venous group. An exploratory Bayesian analysis 
(in the modified intention-to-treat population) 
was used to assess robustness to the noninferi-
ority margin.
Continuous end points were analyzed with 
the use of adjusted quantile regression or rank-
sum tests. Categorical data were compared with 
the chi-square test or Fisher’s exact test. Sub-
group analyses for definitive treatment failure 
considered point estimates and 95% confidence 
intervals rather than the 7.5-percentage-point non-
inferiority margin. Prespecified subgroup analy-
ses were performed for baseline diagnostic cer-
tainty, surgical procedure, infecting pathogen, 
the antibiotic that the clinician had intended to 
prescribe (excluding rifampin) before randomiza-
tion, and clinician-specified intention specifically 
for adjunctive rifampin. Post hoc subgroup analy-
ses were performed for metal retention, identified 
pathogen (as compared with culture-negative) 
infection, use of local antibiotics, and peripheral 
vascular disease. Subgroup analyses were con-
sidered supplementary and were not adjusted for 
multiple testing. All analyses were performed 
with Stata software, version 14SE (StataCorp).
R esult s
Participants
We recruited 1054 participants (including 228 
from the single-center internal pilot study) across 
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26 U.K. sites (median, 8 participants per site; 
interquartile range, 4 to 24) between June 2010 
and October 2015. Of the 42 participants who 
did not complete follow-up, 39 had no end-point 
data recorded; the modified intention-to-treat 
analysis therefore included 1015 participants. The 
per-protocol analysis included 909 participants 
(Fig. 1).
The participants were well matched with re-
gard to baseline characteristics (Table 1, and 
Table S1 in the Supplementary Appendix); 639 of 
the 1054 participants (60.6%) had metalware-
related infection, and 80 (7.6%) were treated 
without surgical intervention. The baseline diag-
nosis of infection was determined on the basis 
of clinical findings in 558 of 1054 participants 
(52.9%) and, in cases in which samples were 
submitted, on the basis of microbiologic find-
ings in 802 of 1003 participants (80.0%) and 
histologic findings in 543 of 636 (85.4%). Addi-
tional details are provided in Table S1A in the 
Supplementary Appendix. Investigators and an 
independent assessment committee with members 
who were unaware of the treatment-group assign-
ments used predefined criteria, detailed in the 
Supplementary Appendix, to determine diagnos-
tic certainty at baseline: 954 participants (90.5%) 
had definite infection, 23 (2.2%) had probable 
infection, and 76 (7.2%) had possible infection 
(data were unavailable for 1 participant).
Route and Duration of Antibiotic Therapy
Most participants (93.3% of those in the intrave-
nous group and 89.3% of those in the oral group) 
began their randomly assigned treatment regi-
men within 7 days after surgery or the start of 
antibiotic therapy. In the intravenous group, the 
percentage of participants receiving intravenous 
therapy declined slowly and then fell substan-
tially at 6 weeks, reflecting planned treatment 
changes. Over the same period, approximately 
10% of the participants in the oral group were 
receiving intravenous therapy at any time (Fig. 2A). 
Antibiotic therapy was continued beyond 6 weeks 
for 805 of 1049 participants (76.7%); the median 
total duration of therapy was 78 days (interquar-
tile range, 42 to 99) in the intravenous group 
and 71 days (interquartile range, 43 to 94) in the 
oral group (P = 0.63) (Fig. 2B).
Primary Analysis
Definitive treatment failure, defined according to 
clinical, microbiologic, or histologic criteria (Ta-
ble S2 in the Supplementary Appendix) and ad-
judicated by an end-point committee with mem-
bers who were unaware of the treatment-group 
assignments, occurred in 74 of 506 participants 
(14.6%) in the intravenous group and 67 of 509 
(13.2%) in the oral group. The missing end-point 
data for 39 of 1054 participants (3.7%) were im-
puted (Table S3 in the Supplementary Appendix). 
The difference in the risk of definitive treatment 
failure (oral group vs. intravenous group) in the 
intention-to-treat population was −1.4 percent-
age points (90% confidence interval [CI], −4.9 to 
2.2; 95% CI, −5.6 to 2.9), thus meeting noninfe-
riority criteria based on either the 7.5-percentage-
point or 5-percentage-point margin.
The modified intention-to-treat and per-proto-
col analyses were consistent with the intention-
to-treat analysis (Fig. 3), as was an exploratory 
Bayesian analysis that estimated a 0.1% and 
12.7% probability that oral treatment was at 
least 5 percentage points and at least 1 percent-
age point inferior, respectively, to intravenous 
treatment. A “worst-case” scenario for missing 
data (i.e., one in which it was assumed that, for 
participants with missing data, all those who 
were randomly assigned to receive oral therapy 
and none of those who were randomly assigned 
to receive intravenous therapy had definitive treat-
ment failures) was consistent with noninferiority 
when the 7.5-percentage-point margin was used.
There was no evidence of heterogeneity ac-
cording to center (P = 0.51) (Fig. S1 in the Sup-
plementary Appendix). No predefined or post 
hoc subgroup analyses showed an outcome ad-
vantage of either intravenous or oral therapy 
(P>0.05 for all analyses of heterogeneity) (Fig. S2 
in the Supplementary Appendix), and there was 
no evidence of a significant between-group dif-
ference in the time to treatment failure (P = 0.57) 
(Fig. S3 in the Supplementary Appendix).
Secondary End Points
In the modified intention-to-treat population, 
probable or possible treatment failures occurred 
in 6 of 506 participants (1.2%) in the intravenous 
group and 10 of 509 participants (2.0%) in the 
oral group. The difference (oral minus intrave-
nous) in the risk of any treatment failure (defi-
nite, probable, or possible) was −0.7 percentage 
points (90% CI, −4.4 to 3.1; 95% CI, −5.1 to 3.8) 
(Table S4 in the Supplementary Appendix). Mem-
bers of the end-point committee were unanimous 
in their categorization of 136 of 141 cases (96%) 
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Figure 1. Enrollment, Randomization, and Follow-up.
1054 Underwent randomization
1449 Were eligible
2077 Participants were assessed
for eligibility
628 Were not eligible
126 Had concomitant infection requiring
intravenous therapy
182 Had mild disease that could be treated
with <6 wk of antibiotics
80 Had no suitable oral regimen available
10 Had previous enrollment in the trial
28 Had shock or other features requiring
long-term intravenous therapy
74 Were unlikely to adhere to trial
requirements
6 Had mycobacterial, fungal, parasitic,
or viral infection
122 Had reasons not reported 
395 Did not undergo randomization
72 Preferred intravenous treatment
44 Preferred oral treatment
6 Had surgeons who did not want them
to participate
10 Left to go abroad
27 Transferred to another hospital
49 Had other reason
187 Declined to participate without
providing further reason
527 Were assigned to the intravenous group
458 Received at least 4 wk of their
assigned treatment strategy
527 Were assigned to the oral group
478 Received at least 4 wk of their
assigned treatment strategy
84 Were excluded from
per-protocol analysis
15 Were missing end-
point data
63 Had <4 wk of assigned
strategy for reasons
other than possible
or probable recurrence
6 Had both missing data
and <4 wk of assigned
strategy
61 Were excluded from
per-protocol analysis
13 Were missing end-
point data
43 Had <4 wk of assigned
strategy for reasons
other than possible
or probable recurrence
5 Had both missing data
and <4 wk of assigned
strategy
22 Did not complete follow-up
7 Withdrew from trial
5 Were lost to follow-up
10 Died
20 Did not complete follow-up
7 Withdrew from trial
7 Were lost to follow-up
6 Died
527 Were included in the primary intention-
to-treat analysis
506 Were included in the modified 
intention-to-treat population
21 Did not have end-point data
527 Were included in the primary intention-
to-treat analysis
509 Were included in the modified 
intention-to-treat population
18 Did not have end-point data
443 Were included in the per-protocol analysis 466 Were included in the per-protocol analysis
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Characteristic
Intravenous Group 
(N = 527)
Oral Group 
(N = 527)
Total 
(N = 1054)
Age — yr
Median (interquartile range) 61 (49–70) 60 (49–70) 60 (49–70)
Range 18–92 18–91 18–92
Male sex — no. (%) 320 (60.7) 358 (67.9) 678 (64.3)
Baseline surgical procedure — no. (%)
No implant or device present; débridement of chronic osteomy-
elitis performed
153 (29.0) 169 (32.1) 322 (30.6)
No implant or device present; débridement of chronic osteomy-
elitis not performed
25 (4.7) 29 (5.5) 54 (5.1)
Débridement and implant retention 124 (23.5) 123 (23.3) 247 (23.4)
Removal of orthopedic device for infection 89 (16.9) 78 (14.8) 167 (15.8)
Prosthetic joint implant removed 68 (12.9) 67 (12.7) 135 (12.8)
Prosthetic joint implant, one-stage revision 47 (8.9) 43 (8.2) 90 (8.5)
Surgery for diskitis, spinal osteomyelitis, or epidural abscess; 
débridement performed
8 (1.5) 5 (0.9) 13 (1.2)
Surgery for diskitis, spinal osteomyelitis, or epidural abscess; 
débridement not performed
13 (2.5) 13 (2.5) 26 (2.5)
Deep-tissue histologic result — no. (%)
Infected 266 (50.5) 277 (52.6) 543 (51.5)
Equivocal 13 (2.5) 17 (3.2) 30 (2.8)
Uninfected 31 (5.9) 32 (6.1) 63 (6.0)
Not done or missing† 217 (41.2) 201 (38.1) 418 (39.7)
Microbiologic diagnostic sampling — no. (%)
Two or more samples positive for same organism 357 (67.7) 338 (64.1) 695 (65.9)
Two or more samples taken but only one positive for a given 
pathogenic organism
20 (3.8) 32 (6.1) 52 (4.9)
Only one sample taken, which was found to be positive for a 
pathogenic organism by closed biopsy
25 (4.7) 30 (5.7) 55 (5.2)
Two or more samples taken but only one positive for a given 
nonpathogenic organism
21 (4.0) 25 (4.7) 46 (4.4)
Sampling undertaken but no organisms identified 77 (14.6) 78 (14.8) 155 (14.7)
Not done or missing‡ 27 (5.1) 24 (4.6) 51 (4.8)
Organisms identified — no./total no. (%)§
Staphylococcus aureus 196/500 (39.2) 182/503 (36.2) 378/1003 (37.7)
Coagulase-negative staphylococcus 137/500 (27.4) 135/503 (26.8) 272/1003 (27.1)
Streptococcus species 72/500 (14.4) 73/503 (14.5) 145/1003 (14.5)
Pseudomonas species 28/500 (5.6) 23/503 (4.6) 51/1003 (5.1)
Other gram-negative organisms 84/500 (16.8) 84/503 (16.7) 168/1003 (16.7)
Culture negative 77/500 (15.4) 78/503 (15.5) 155/1003 (15.5)
*  There was no significant difference between the groups for any variable shown other than sex (P = 0.02). Percentages may not total 100 be-
cause of rounding. Additional baseline characteristics are shown in Table S1 in the Supplementary Appendix.
†  For 409 participants (212 in the intravenous group and 197 in the oral group), no tissue samples were submitted for histologic examination; 
for 9 participants (5 in the intravenous group and 4 in the oral group), the results of histologic analysis were missing.
‡  For 42 participants (22 in the intravenous group and 20 in the oral group), no tissue samples were submitted for microbiologic examina-
tion; for 9 participants (5 in the intravenous group and 4 in the oral group), the results of microbiologic analysis were missing.
§  More than one option was possible: 153 participants had polymicrobial infection with two organisms, and 28 had polymicrobial infection 
with three or more organisms; 45 isolates were not in the listed subgroups.
Table 1. Baseline Characteristics of the Trial Participants.*
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as definite treatment failure and 13 of 16 cases 
(81%) as probable or possible treatment failure. 
Consensus on the remaining 8 cases was 
achieved by discussion.
Early discontinuation of the randomly as-
signed treatment strategy was more common in 
the intravenous group than in the oral group (99 
of 523 participants [18.9%] vs. 67 of 523 [12.8%], 
P = 0.006), as were complications associated with 
the intravenous catheter (49 of 523 [9.4%] vs. 5 of 
523 [1.0%], P<0.001). There was no significant 
difference in the incidence of C. difficile–associ-
ated diarrhea (9 of 523 [1.7%] in the intravenous 
group and 5 of 523 [1.0%] in the oral group, 
P = 0.30) or the percentage of participants re-
porting at least one serious adverse event (146 of 
527 [27.7%] in the intravenous group and 138 of 
527 (26.2%) in the oral group, P = 0.58) (Table 2). 
The median hospital stay was significantly longer 
in the intravenous group than in the oral group 
(14 days [interquartile range, 11 to 21] vs. 11 days 
[interquartile range, 8 to 20], P<0.001) (Fig. S4 in 
the Supplementary Appendix).
Patient-Reported Outcome Measures
The median EQ-5D-3L score, Oxford Hip Score, 
and Oxford Knee Score improved over time in 
both groups. At days 120 and 365, neither the 
EQ-5D-3L nor the Oxford Hip Score differed 
significantly between the groups (P = 0.61 and 
P = 0.18, respectively), but better Oxford Knee 
Scores were observed in the oral group than in 
the intravenous group at both time points (P = 0.01 
and P = 0.04, respectively) (Table S5 in the Supple-
mentary Appendix).
Adherence to Treatment
Morisky scores of 6 or higher (indicating medium 
or high adherence) at day 42, which we interpret 
as indicating a limited risk of adherence-related 
treatment failure, were reported by 75 of the 80 
participants (93.8%) in the intravenous group 
who administered their own medication and by 
283 of 323 participants (87.6%) in the oral group 
Figure 2. Route and Duration of Antibiotic Therapy.
Panel A shows the percentage of participants receiving 
intravenous antibiotics from the start of the treatment 
episode (i.e., the date of definitive surgery or, if surgery 
was not performed, the start of planned curative anti-
biotic therapy) through day 60. Participants who had 
been randomly assigned to receive oral therapy and re-
ceived intravenous therapy were doing so because they 
were prescribed intravenous antibiotics for up to 5 days 
for an intercurrent infection unrelated to the incident 
orthopedic infection (permitted by the protocol); were 
unable or unwilling to take oral therapy for any reason 
(secondary end point); were, subsequent to random-
ization, considered to have no suitable oral options for 
antibiotic therapy on the basis of emerging susceptibil-
ity results (secondary end point); or had had a potential 
treatment failure (primary end point). Most participants 
who had been randomly assigned to receive intravenous 
therapy but were receiving oral therapy over the same 
period were doing so because of a failure of intravenous 
access (secondary end point). Panel B shows the per-
centage of participants receiving any antibiotic through 
the final follow-up. The vertical line indicates 6 weeks 
after the start of treatment (i.e., the end of the inter-
vention period).
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(Table S6 in the Supplementary Appendix). Data 
from the participants in the oral group, whose 
adherence was monitored by means of a Medica-
tion Event Monitoring System, showed higher 
than 95% dose-by-dose adherence in 56 of 62 
participants (90.3%); 154 of 4060 planned doses 
(3.8%) were not taken (Table S7 in the Supple-
mentary Appendix).
Planned Antibiotic Therapy
The intravenous and oral antibiotic regimens that 
had originally been planned by the participants’ 
physicians were documented before randomiza-
tion for 917 and 945 participants, respectively. 
The most frequently planned intravenous antibi-
otics were glycopeptides (380 of 917 participants 
[41.4%]) and cephalosporins (345 of 917 [37.6%]) 
(Table S8 in the Supplementary Appendix). The 
most frequently planned oral antibiotics (exclud-
ing rifampin) were quinolones (414 of 945 par-
ticipants [43.8%]) and combination oral therapy 
(133 of 945 [14.1%]) (Table S9 in the Supplemen-
tary Appendix). Outcomes did not vary signifi-
cantly between the groups according to the in-
tended intravenous or oral antibiotic agent (P = 0.42 
and P = 0.80, respectively, for heterogeneity) (Fig. 
S2 in the Supplementary Appendix). The actual 
antibiotics prescribed (excluding rifampin), de-
fined by use for at least 7 days during the initial 
6-week treatment period, were most commonly 
glycopeptides (214 of 521 participants [41.1%]) 
and cephalosporins (173 of 521 [33.2%]) in the 
intravenous group and quinolones (191 of 523 
[36.5%]) and combination therapy (87 of 523 
[16.6%]) in the oral group (Table S10 in the 
Supplementary Appendix).
The intended use of adjunctive oral rifampin 
was analyzed separately; it was included with 
planned intravenous therapy for 142 of 917 par-
ticipants (15.5%) and with planned oral therapy 
in 487 of 945 participants (51.5%). Outcomes did 
not vary significantly according to intended use 
of rifampin (P = 0.22 for heterogeneity) (Fig. S2 
in the Supplementary Appendix). The addition of 
adjunctive rifampin was permitted at any time 
after randomization; 120 of 523 participants 
(22.9%) in the intravenous group and 165 of 526 
participants (31.4%) in the oral group received 
rifampin for at least 6 weeks between random-
ization and final follow-up (Table S11 in the 
Supplementary Appendix).
Discussion
In this trial, with regard to treatment failure as-
sessed at 1 year, oral antibiotic therapy was non-
inferior to intravenous antibiotic therapy when 
used during the first 6 weeks of treatment for 
bone and joint infection; our results thereby 
challenge a widely accepted standard of care.4,15,16 
Subgroup analyses did not identify significant 
heterogeneity, irrespective of baseline surgical 
Figure 3. Differences in Risk According to the Analysis Performed.
The point estimates for the differences in failure rates are shown with 90% (thick lines) and 95% (thin lines) two-sided confidence inter-
vals. The noninferiority margin is indicated by the vertical dashed line. The use of two-sided 90% confidence intervals was prespecified 
in the trial protocol in accordance with the sample-size calculation. Because two-sided 95% confidence intervals are also now commonly 
included in noninferiority trials, they are shown here to assess the sensitivity of the results to a change in significance level. In the intention-
to-treat population, missing data were imputed with the use of multiple imputation by chained equations. The modified intention-to-treat 
population included only the participants with complete end-point data. The worst-case sensitivity analysis shows the results based on 
the worst-case assumption that, for participants with missing data, all participants who were randomly assigned to receive oral therapy 
and no participants who were randomly assigned to receive intravenous therapy had definitive treatment failures, thus introducing the 
worst possible bias against the oral strategy.
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Event or End Point
Intravenous Group 
(N = 527)
Oral Group 
(N = 527)
Total 
(N = 1054)
Participants with at least one serious adverse event — no. (%)* 146 (27.7) 138 (26.2) 284 (26.9)
Classification of serious adverse events — no. of events/total no. (%)†
Related to operative site‡ 46/220 (20.9) 69/224 (30.8) 115/444 (25.9)
Antibiotic-related§ 30/220 (13.6) 15/224 (6.7) 45/444 (10.1)
Frailty-related¶ 10/220 (4.5) 5/224 (2.2) 15/444 (3.4)
Neurologic 4/220 (1.8) 10/224 (4.5) 14/444 (3.2)
Cardiovascular 26/220 (11.8) 29/224 (12.9) 55/444 (12.4)
Respiratory 14/220 (6.4) 21/224 (9.4) 35/444 (7.9)
Gastrointestinal 21/220 (9.5) 13/224 (5.8) 34/444 (7.7)
Renal 2/220 (0.9) 8/224 (3.6) 10/444 (2.3)
Diabetic 7/220 (3.2) 10/224 (4.5) 17/444 (3.8)
Genitourinary 9/220 (4.1) 4/224 (1.8) 13/444 (2.9)
Neoplastic 4/220 (1.8) 6/224 (2.7) 10/444 (2.3)
Musculoskeletal, not related to original site 17/220 (7.7) 21/224 (9.4) 38/444 (8.6)
Skin and soft tissue, not related to original site 10/220 (4.5) 7/224 (3.1) 17/444 (3.8)
Other events‖ 3/220 (1.4) 0/224 3/444 (0.7)
Deaths from any cause** 17/220 (7.7) 6/224 (2.7) 23/444 (5.2)
Serious adverse events occurring during first 6 wk of therapy 76/220 (34.5) 77/224 (34.4) 153/444 (34.5)
Secondary end points — no. of participants/total no. (%)††
Intravenous catheter complications‡‡ 49/523 (9.4) 5/523 (1.0) 54/1046 (5.2)
Episode of C. difficile–associated diarrhea§§ 9/523 (1.7) 5/523 (1.0) 14/1046 (1.3)
Early discontinuation of randomly assigned treatment strategy¶¶ 99/523 (18.9) 67/523 (12.8) 166/1046 (15.9)
*  Shown are participants reporting at least one serious adverse event unrelated to intravenous catheter complications, C. difficile–associated 
diarrhea, or early discontinuation of the randomly assigned treatment strategy (P = 0.58).
†  A total of 444 serious adverse events (unrelated to catheter complications, C. difficile–associated diarrhea, or early discontinuation of the 
randomly assigned treatment strategy) were reported among 284 participants.
‡  This category includes prolongation of hospital stay or readmission for symptom control, wound management, mobility, skin and soft tis-
sue infection, dislocation, or a recurrent primary end-point event.
§  The antibiotic-related events listed here met the definition of a serious adverse event and were attributed by the responsible infection spe-
cialist to antibiotic therapy (rather than to unrelated coexisting conditions). They included acute kidney injury (5 events), allergic reactions 
requiring immediate intervention (5), confusion (5), drug-induced fever (6), severe gastrointestinal symptoms (8), severe skin reactions 
(including suspected Stephens–Johnson syndrome) (7), eosinophilic pneumonitis (2), neutropenia or thrombocytopenia (4), tendonitis (1), 
hepatitis (1), and cardiac arrhythmia (1).
¶  Frailty-related severe adverse events included slips, trips, or falls in elderly participants or readmission as a result of an inability to live at 
home (e.g., because of problems with mobility, safety, or cognitive impairment).
‖  Other events in the intravenous group included foreign body in eye, acute Epstein–Barr virus infection, alcohol withdrawal, and opiate overdose.
**  There were 3 deaths within 30 days after randomization, all in the intravenous group; 1 each was attributed to pneumonia, sepsis second-
ary to infected leg ulcers, and C. difficile–associated toxic megacolon. Of the remaining 20 deaths, 7 (5 in the intravenous group and 2 in 
the oral group) were attributed to cardiovascular disease, 5 (4 in the intravenous group and 1 in the oral group) to pneumonia, 4 (3 in the 
intravenous group and 1 in the oral group) to underlying neoplasia, and 1 (in the intravenous group) to spontaneous bacterial peritonitis. 
The cause of death in 3 patients (1 in the intravenous group and 2 in the oral group) was not reported.
††  Intravenous catheter complications, C. difficile–associated diarrhea, and early discontinuation of the randomly assigned treatment strategy 
were secondary end points and were not classified as serious adverse events for the purposes of this analysis. In 8 cases (4 in each group), 
no data were submitted. In 3 cases (2 in the intravenous group and 1 in the oral group), data were carried forward after censoring.
‡‡  Intravenous catheter complications included mechanical failure (24 of 49 participants in the intravenous group, 3 of 5 in the oral group), 
thrombosis or thrombophlebitis (13 of 49 in the intravenous group, 1 of 5 in the oral group), and catheter-related infection (12 of 49 in 
the intravenous group, 1 of 5 in the oral group). In the intravenous group, catheter complications resulted in removal of the catheter in 42 
of 49 participants in the intravenous group and in 4 of 5 participants in the oral group. Overall P<0.001 for the between-group compari-
son. Four patients who were randomly assigned to the oral group had a catheter complication after having been switched to intravenous 
therapy after meeting an end point; 1 patient who was randomly assigned to the oral group had a catheter complication arising from an 
unrelated clinical episode several months after the initial 6-week follow-up period.
§§  The between-group difference in the risk of C. difficile–associated diarrhea was −0.8 percentage points (95% confidence interval, −2.2 to 
0.6; P = 0.30 by Fisher’s exact test).
¶¶  Reasons for early discontinuation of the randomly assigned treatment strategy included difficulties with intravenous access or administra-
tion (41 of 99 participants in the intravenous group and 0 of 67 in the oral group), antibiotic adverse effects (26 of 99 in the intravenous 
group and 23 of 67 in the oral group), patient preference (19 of 99 in the intravenous group and 5 of 67 in the oral group), intercurrent ill-
ness (2 of 99 in the intravenous group and 8 of 67 in the oral group), possible or probable recurrence (1 of 99 in the intravenous group 
and 15 of 67 in the oral group), good clinical response (1 of 99 in the intravenous group and 0 of 67 in the oral group), and other reasons 
(9 of 99 in the intravenous group and 15 of 67 in the oral group). The reason was not available for 0 of 99 in the intravenous group and  
1 of 67 in the oral group. Overall P = 0.006 for the between-group comparison, by Pearson’s chi-square test.
Table 2. Serious Adverse Events and Secondary End Points.
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procedure, retention of metalware, pathogen, or 
intended antibiotics at randomization. Oral ther-
apy was associated with shorter hospital stays 
and fewer complications than intravenous ther-
apy. Oral therapy may not be appropriate for 
some patients (e.g., those with poor enteral ab-
sorption) and pathogens (e.g., those with resis-
tance to oral agents).
The participants in this trial represented the 
broader patient population, as indicated by the 
choice of antibiotics9 and the pathogens identi-
fied.17,18 Most participants followed their random-
ly assigned treatment strategy, and trial retention 
was high, indicating that the trial design and 
interventions were generally acceptable. Adher-
ence to oral medication was good; the investiga-
tors provided advice regarding adherence but did 
not use trial-specific adherence tools such as text 
reminders.
Our trial had some limitations. It was neces-
sarily open label; it would have been impractical 
to produce matched placebo for each antibiotic 
that might have been prescribed and would have 
been unethical to expose participants in the oral 
group to the risks associated with intravenous 
administration of placebo for 6 weeks. Objective 
end-point criteria and an end-point committee 
with members who were unaware of the treat-
ment-group assignments minimized potential 
bias due to the open-label design.
We were concerned that participants in the 
oral group might be prescribed longer follow-on 
courses of antibiotics than the participants in the 
intravenous group. In fact, the total treatment 
duration did not differ between the groups 
(Fig. 2B). Participants in the intravenous group 
probably had more frequent health care assess-
ments than did those in the oral group, but 
treatment failure was not identified earlier in the 
intravenous group (Fig. S3 in the Supplementary 
Appendix), which suggests that there was no 
clinically important variation in postrandomiza-
tion surveillance.
In this trial, we did not seek to compare 
specific antibiotic agents or to stipulate which 
agents should be used. We relied on the exper-
tise of the consulting infectious-disease special-
ist to select and adjust antibiotic regimens, taking 
into account factors such as susceptibilities, risk 
of the emergence of resistance, bioavailability, 
tissue penetration, side effects, coexisting condi-
tions, and drug interactions. This strategy carries 
a risk that, in some cases, the preferred antibi-
otic as defined by in vitro testing may not have 
been prescribed, but this risk would have been 
mitigated by the oversight of an accredited spe-
cialist in infectious diseases selecting the appro-
priate therapy for individual participants, consis-
tent with real-world practice.
Rifampin, which is considered by many to be 
an important agent in the treatment of certain 
biofilm-associated infections, was more common-
ly planned as treatment in early antibiotic regi-
mens in the oral group than in the intravenous 
group, although a subgroup analysis showed no 
significant effect of planned use on outcome. 
Actual rifampin use at any time during treatment 
varied less between the groups than planned use, 
which suggests that the timing of adjunctive 
rifampin treatment was influenced by the ran-
domly assigned treatment strategy.
This trial was deliberately inclusive: there was 
no selection according to infecting organism, 
surgical procedure, or anatomic site. Although the 
resulting trial population was heterogeneous, 
the advantages of generalizability outweigh the 
disadvantages of heterogeneity. A more selective 
recruitment strategy, such as inclusion of only 
primary arthroplasty infections with Staphylococcus 
aureus, would have made the trial prohibitively 
long and would have limited the utility of the 
results. The trial hypothesis was based on the 
pharmacokinetic principle that appropriately se-
lected oral agents provide adequate antibiotic 
concentrations at the site of infection. This princi-
ple is unlikely to have been differentially affected 
by, for example, the anatomic site, presence of 
metalwork, or extent of surgical débridement. 
However, selection of the appropriate oral agents 
necessarily relied on a clear understanding of 
the relevant pharmacologic variables and close 
liaison between surgical and infectious-disease 
specialists.
Causal attribution of serious adverse events 
related to antibiotics was determined by the re-
sponsible infectious-disease specialist. Given that 
these were necessarily based on subjective assess-
ments, they may have been liable to potential 
biases of unknown effect. Because the partici-
pants in the trial were followed up for only 1 year, 
we cannot rule out the possibility that the risk 
of later treatment failure, which is known to oc-
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cur with osteomyelitis, may differ between the 
trial groups.
We found that appropriately selected oral anti-
biotic therapy was noninferior to intravenous 
therapy when used during the first 6 weeks in 
the management of bone and joint infection, as 
assessed by treatment failure within 1 year. Oral 
antibiotic therapy was associated with a shorter 
length of hospital stay and with fewer complica-
tions than intravenous therapy.
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